Chrna7 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| CHRNA7 | |
|---|---|
| Full Name | Cholinergic Receptor Nicotinic Alpha 7 Subunit |
| Chromosome | 15q13.3 |
| NCBI Gene ID | 1139 |
| OMIM | 100511 |
| Ensembl ID | ENSG00000175344 |
| UniProt ID | P36544 |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Schizophrenia, Epilepsy, Rett Syndrome |
The nicotinic acetylcholine receptor alpha 7 (α7 nAChR) is a homomeric ligand-gated ion channel highly expressed in the brain, particularly in the hippocampus, cortex, and basal ganglia. α7 nAChR exhibits high calcium permeability and rapidly desensitizes upon agonist binding. It plays crucial roles in cognitive functions including attention, memory, and learning. In Alzheimer's disease, α7 nAChR density is reduced in the hippocampus, and the receptor interacts with amyloid-beta, contributing to synaptic dysfunction. Agonists of α7 nAChR (including nicotine) have shown promise in preclinical models for enhancing cognition and providing neuroprotection.
The CHRNA7 gene spans approximately 45 kb on chromosome 15q13.3 and consists of 10 exons. The gene encodes a protein of 502 amino acids. Alternative splicing produces multiple transcript variants, with the canonical isoform being the most widely expressed. The promoter region contains binding sites for multiple transcription factors including SP1, AP2, and NF-κB, suggesting regulation by neuronal activity and inflammatory signals.
The α7 nAChR is a pentameric ligand-gated ion channel composed of five identical α7 subunits. Each subunit contains:
The receptor has high permeability to calcium (PCa/PNa ≈ 10-20), making it uniquely positioned to activate intracellular calcium-dependent signaling pathways including CaMKII, PKC, and MAPK.
| Drug/Compound | Status | Notes |
|---|---|---|
| PNU-282987 | Research | Selective α7 agonist |
| A-582941 | Research | Brain-penetrant agonist |
| EVP-6124 | Clinical Trials | Cognitive enhancement in AD |
| GTS-21 | Clinical Trials | Schizophrenia cogition |
Several clinical trials have evaluated α7 nAChR agonists:
The study of Chrna7 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.